NICE recommends novel immunotherapy for leukaemia
The agency’s decision means eligible adult patients in the UK are set to access the combination immunotherapy as a new treatment option for acute lymphoblastic leukaemia (ALL).
Čítajte ďalej na https://www.europeanpharmaceuticalreview.com/news/249342/nice-recommends-novel-immunotherapy-for-leukaemia/